Akebia Therapeutics, Inc. logo

Akebia Therapeutics, Inc.

NASDAQ:AKBA

Overview | Financials
Company Name Akebia Therapeutics, Inc.
Symbol AKBA
Currency USD
Price 1.95
Market Cap 425,452,950
Dividend Yield 0%
52-week-range 0.8 - 2.48
Industry Biotechnology
Sector Healthcare
CEO Mr. John P. Butler MBA
Website https://www.akebia.com

An error occurred while fetching data.

About Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent

Related Stocks

Orgenesis Inc. logo

Orgenesis Inc.

ORGS

2.84 USD

DiaMedica Therapeutics Inc. logo

DiaMedica Therapeutics Inc.

DMAC

5.41 USD

Streamline Health Solutions, Inc. logo

Streamline Health Solutions, Inc.

STRM

3.68 USD

InflaRx N.V. logo

InflaRx N.V.

IFRX

2.59 USD

Novo Integrated Sciences, Inc. logo

Novo Integrated Sciences, Inc.

NVOS

0.06 USD

MediWound Ltd. logo

MediWound Ltd.

MDWD

17.7 USD

Rain Therapeutics Inc. logo

Rain Therapeutics Inc.

RAIN

1.21 USD

Financials

Numbers are in millions USD

Numbers are in millions USD